NO20050054L - Nye, kondenserte imidazolderivater - Google Patents

Nye, kondenserte imidazolderivater

Info

Publication number
NO20050054L
NO20050054L NO20050054A NO20050054A NO20050054L NO 20050054 L NO20050054 L NO 20050054L NO 20050054 A NO20050054 A NO 20050054A NO 20050054 A NO20050054 A NO 20050054A NO 20050054 L NO20050054 L NO 20050054L
Authority
NO
Norway
Prior art keywords
optionally substituted
new
imidazole derivatives
condensed imidazole
alkyl
Prior art date
Application number
NO20050054A
Other languages
English (en)
Norwegian (no)
Inventor
Hironori Ikuta
Tadashi Nagakura
Nobuyuki Yasuda
Eita Emori
Kazuto Yamazaki
Seiji Yoshikawa
Fumiyosi Matsuura
Clark Richard
Kazunobu Kira
Original Assignee
Eisai Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai Co Ltd filed Critical Eisai Co Ltd
Publication of NO20050054L publication Critical patent/NO20050054L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/28—Oxygen atom
    • C07D473/30—Oxygen atom attached in position 6, e.g. hypoxanthine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/36—Sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/40—Heterocyclic compounds containing purine ring systems with halogen atoms or perhalogeno-alkyl radicals directly attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NO20050054A 2002-06-06 2005-01-05 Nye, kondenserte imidazolderivater NO20050054L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2002166069 2002-06-06
JP2002209373 2002-07-18
JP2002307750 2002-10-23
PCT/JP2003/007010 WO2003104229A1 (fr) 2002-06-06 2003-06-03 Nouveau derive d'imidazole fondu

Publications (1)

Publication Number Publication Date
NO20050054L true NO20050054L (no) 2005-02-10

Family

ID=29740540

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20050054A NO20050054L (no) 2002-06-06 2005-01-05 Nye, kondenserte imidazolderivater

Country Status (19)

Country Link
US (4) US20060100199A1 (fr)
EP (1) EP1514552A4 (fr)
JP (2) JP3675813B2 (fr)
KR (1) KR100985160B1 (fr)
CN (2) CN100469778C (fr)
AU (1) AU2003241960B2 (fr)
BR (1) BR0311697A (fr)
CA (1) CA2485641C (fr)
HK (2) HK1100219A1 (fr)
IL (1) IL165178A0 (fr)
IS (1) IS7625A (fr)
MX (1) MXPA04012226A (fr)
NO (1) NO20050054L (fr)
NZ (1) NZ536794A (fr)
PL (1) PL374007A1 (fr)
RU (1) RU2297418C9 (fr)
TW (1) TWI273104B (fr)
WO (1) WO2003104229A1 (fr)
ZA (1) ZA200500041B (fr)

Families Citing this family (129)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001268958B2 (en) * 2000-07-04 2006-03-09 Novo Nordisk A/S Heterocyclic compounds, which are inhibitors of the enzyme dpp-iv
PT1757606E (pt) * 2001-02-24 2009-05-26 Boehringer Ingelheim Pharma Utilização de derivados de xantina como produto farmacêutico, bem como seu processo de preparação
EP1338595B1 (fr) 2002-02-25 2006-05-03 Eisai Co., Ltd. Dérivés de Xanthines servant d'inhibiteurs de DPP-IV
EP1514552A4 (fr) * 2002-06-06 2008-04-02 Eisai R&D Man Co Ltd Nouveau derive d'imidazole fondu
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US7569574B2 (en) * 2002-08-22 2009-08-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Purine derivatives, the preparation thereof and their use as pharmaceutical compositions
US7495005B2 (en) 2002-08-22 2009-02-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Xanthine derivatives, their preparation and their use in pharmaceutical compositions
MXPA05003252A (es) * 2002-09-26 2005-07-05 Eisai Co Ltd Farmaco de combinacion.
US7482337B2 (en) 2002-11-08 2009-01-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions
DE10254304A1 (de) * 2002-11-21 2004-06-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Xanthinderivate, deren Herstellung und deren Verwendung als Arzneimittel
US7109192B2 (en) 2002-12-03 2006-09-19 Boehringer Ingelheim Pharma Gmbh & Co Kg Substituted imidazo-pyridinones and imidazo-pyridazinones, the preparation thereof and their use as pharmaceutical compositions
UY28103A1 (es) * 2002-12-03 2004-06-30 Boehringer Ingelheim Pharma Nuevas imidazo-piridinonas sustituidas, su preparación y su empleo como medicacmentos
NZ540495A (en) 2002-12-04 2007-09-28 Eisai R&D Man Co Ltd 1,3-Dihydro-imidazole fused-ring compound
EP1608317B1 (fr) 2003-03-25 2012-09-26 Takeda Pharmaceutical Company Limited Inhibiteurs de dipeptidyle peptidase
JPWO2004096806A1 (ja) * 2003-04-30 2006-07-13 大日本住友製薬株式会社 縮合イミダゾール誘導体
US7371871B2 (en) 2003-05-05 2008-05-13 Probiodrug Ag Inhibitors of glutaminyl cyclase
AU2003902828A0 (en) * 2003-06-05 2003-06-26 Fujisawa Pharmaceutical Co., Ltd. Dpp-iv inhibitor
DE10327439A1 (de) * 2003-06-18 2005-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Imidazopyridazinon- und Imidazopyridonderivate, deren Herstellung und deren Verwendung als Arzneimittel
US7566707B2 (en) * 2003-06-18 2009-07-28 Boehringer Ingelheim International Gmbh Imidazopyridazinone and imidazopyridone derivatives, the preparation thereof and their use as pharmaceutical compositions
US7470700B2 (en) * 2003-08-13 2008-12-30 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US7169926B1 (en) 2003-08-13 2007-01-30 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US7678909B1 (en) 2003-08-13 2010-03-16 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
JP2007505121A (ja) 2003-09-08 2007-03-08 武田薬品工業株式会社 ジペプチジルぺプチダーゼ阻害剤
JPWO2005051949A1 (ja) * 2003-11-26 2007-06-21 住友製薬株式会社 新規縮合イミダゾール誘導体
DE10355304A1 (de) 2003-11-27 2005-06-23 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 8-(Piperazin-1-yl)-und 8-([1,4]Diazepan-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
WO2005053695A1 (fr) * 2003-12-04 2005-06-16 Eisai Co., Ltd. Agent preventif ou therapeutique de la sclerose en plaques
WO2005061505A1 (fr) * 2003-12-16 2005-07-07 Pfizer Products Inc. Composes bicycliques d'imidazolyle pyrimidin-4-one en tant que ligands des recepteurs cannabinoides et leurs utilisations
US7217711B2 (en) 2003-12-17 2007-05-15 Boehringer Ingelheim International Gmbh Piperazin-1-yl and 2-([1,4]diazepan-1-yl)-imidazo[4,5-d]-pyridazin-4-ones, the preparation thereof and their use as pharmaceutical compositions
DE10359098A1 (de) * 2003-12-17 2005-07-28 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 2-(Piperazin-1-yl)- und 2-([1,4]Diazepan-1-yl)-imidazo[4,5-d]pyridazin-4-one, deren Herstellung und deren Verwendung als Arzneimittel
DE10360835A1 (de) * 2003-12-23 2005-07-21 Boehringer Ingelheim Pharma Gmbh & Co. Kg Bicyclische Imidazolverbindungen, deren Herstellung und deren Verwendung als Arzneimittel
DK1758905T3 (da) * 2004-02-18 2009-08-24 Boehringer Ingelheim Int 8-[3-amino-piperidin-1-yl]-xanthiner, deres fremstilling og deres anvendelse som DPP-IV-hæmmer
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004009039A1 (de) * 2004-02-23 2005-09-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-[3-Amino-piperidin-1-yl]-xanthine, deren Herstellung und Verwendung als Arzneimittel
US7732446B1 (en) 2004-03-11 2010-06-08 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US7393847B2 (en) 2004-03-13 2008-07-01 Boehringer Ingleheim International Gmbh Imidazopyridazinediones, their preparation and their use as pharmaceutical compositions
DE102004012366A1 (de) * 2004-03-13 2005-09-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Imidazopyridazindione, deren Herstellung und deren Verwendung als Arzneimittel
AU2004318013B8 (en) 2004-03-15 2011-10-06 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
WO2005100346A1 (fr) * 2004-04-08 2005-10-27 Wyeth Derives thioamide utiles en tant que modulateurs des recepteurs de la progesterone
US7179809B2 (en) * 2004-04-10 2007-02-20 Boehringer Ingelheim International Gmbh 2-Amino-imidazo[4,5-d]pyridazin-4-ones, their preparation and their use as pharmaceutical compositions
CA2561210A1 (fr) * 2004-04-10 2005-10-20 Boehringer Ingelheim International Gmbh Nouvelles 2-amino-imidazo[4,5-d]pyridazin-4-ones et 2-amino-imidazo[4,5-c]pyridin-4-ones, leur production et leur utilisation comme medicaments
US7439370B2 (en) 2004-05-10 2008-10-21 Boehringer Ingelheim International Gmbh Imidazole derivatives, their preparation and their use as intermediates for the preparation of pharmaceutical compositions and pesticides
DE102004022970A1 (de) * 2004-05-10 2005-12-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Imidazolderivate, deren Herstellung und deren Verwendung als Intermediate zur Herstellung von Arzneimitteln und Pestiziden
JP2008501714A (ja) 2004-06-04 2008-01-24 武田薬品工業株式会社 ジペプチジルペプチダーゼインヒビター
DE102004030502A1 (de) 2004-06-24 2006-01-12 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Imidazole und Triazole, deren Herstellung und Verwendung als Arzneimittel
WO2006019965A2 (fr) 2004-07-16 2006-02-23 Takeda San Diego, Inc. Inhibiteurs de la dipeptidyl peptidase
DE102004038269A1 (de) * 2004-08-06 2006-03-16 Sanofi-Aventis Deutschland Gmbh Substituierte, bizyklische 8-Piperidino-xanthine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE102004043944A1 (de) 2004-09-11 2006-03-30 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 8-(3-Amino-piperidin-1-yl)-7-(but-2-inyl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
DE102004044221A1 (de) 2004-09-14 2006-03-16 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 3-Methyl-7-butinyl-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
AR051596A1 (es) * 2004-10-26 2007-01-24 Irm Llc Compuestos heterociclicos condensados nitrogenados como inhibidores de la actividad del receptor canabinoide 1; composiciones farmaceuticas que los contienen y su empleo en la preparacion de medicamentos para el tratamiento de trastornos alimentarios
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
JP2008524331A (ja) 2004-12-21 2008-07-10 武田薬品工業株式会社 ジペプチジルペプチダーゼ阻害剤
MX2007007483A (es) * 2004-12-24 2007-07-20 Dainippon Sumitomo Pharma Co Derivados de pirroles biciclicos.
DOP2006000008A (es) 2005-01-10 2006-08-31 Arena Pharm Inc Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1
JPWO2006112331A1 (ja) * 2005-04-13 2008-12-11 大日本住友製薬株式会社 新規縮合ピロール誘導体
DE102005035891A1 (de) * 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
CN101232873A (zh) * 2005-08-11 2008-07-30 霍夫曼-拉罗奇有限公司 含有dpp-iv抑制剂的药物组合物
CA2622472C (fr) 2005-09-14 2013-11-19 Takeda Pharmaceutical Company Limited Inhibiteurs de la dipeptidyl peptidase permettant de traiter le diabete
CN101360723A (zh) 2005-09-16 2009-02-04 武田药品工业株式会社 制备嘧啶二酮衍生物的方法
GB0526291D0 (en) 2005-12-23 2006-02-01 Prosidion Ltd Therapeutic method
WO2007112347A1 (fr) 2006-03-28 2007-10-04 Takeda Pharmaceutical Company Limited Inhibiteurs de la dipeptidyl peptidase
PE20071221A1 (es) * 2006-04-11 2007-12-14 Arena Pharm Inc Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas
DK1971862T3 (da) * 2006-04-11 2011-02-14 Arena Pharm Inc Fremgangsmåder til anvendelse af GPR119-receptor til identificering af forbindelser anvendelige til øgning af knoglemasse hos en person
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
CA2873524C (fr) 2006-05-04 2018-02-20 Boehringer Ingelheim International Gmbh Une forme polymerique de 1-((4-methyl-quinazolin-2-yl)methyl)-3-7-(2-butyn-1-yl)-8-(3-(r)-aminopiperidin-1-yl)xanthine
EP1852108A1 (fr) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG Compositions d'inhibiteurs de la DPP IV
CA2660197A1 (fr) 2006-08-08 2008-02-14 Boehringer Ingelheim International Gmbh Pyrrolo[3,2-d]pyrimidines utilisees en tant qu'inhibiteurs de dpp-iv pour le traitement du diabete sucre
US8324383B2 (en) 2006-09-13 2012-12-04 Takeda Pharmaceutical Company Limited Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
WO2008055945A1 (fr) 2006-11-09 2008-05-15 Probiodrug Ag Dérivés 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one utiles en tant qu' inhibiteurs de la glutaminyl-cyclase dans le traitement des ulcères, du cancer et d'autres maladies
TW200838536A (en) 2006-11-29 2008-10-01 Takeda Pharmaceutical Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
SI2091948T1 (sl) 2006-11-30 2012-07-31 Probiodrug Ag Novi inhibitorji glutaminil ciklaze
US8093236B2 (en) 2007-03-13 2012-01-10 Takeda Pharmaceuticals Company Limited Weekly administration of dipeptidyl peptidase inhibitors
EP2142514B1 (fr) 2007-04-18 2014-12-24 Probiodrug AG Dérivés de thio-urée utilisés comme inhibiteurs de la glutaminyl cyclase
JP2008289437A (ja) * 2007-05-28 2008-12-04 Sony Corp レーザーを用いた酵素活性測定方法及び酵素活性測定装置
ES2733348T3 (es) * 2007-08-17 2019-11-28 Boehringer Ingelheim Int Derivados de purina para uso en el tratamiento de enfermedades relacionadas con FAP
UY31685A (es) * 2008-03-04 2009-11-10 Smithkline Beecham Corp Compuestos antivirales, composiciones y metodos para usarlos
MX2010009873A (es) * 2008-03-10 2010-09-30 Dainippon Sumitomo Pharma Co Compuesto de pirrol biciclico.
PE20140960A1 (es) 2008-04-03 2014-08-15 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
EP2108960A1 (fr) 2008-04-07 2009-10-14 Arena Pharmaceuticals, Inc. Procédés d'utilisation d'un récepteur couplé à protéine G pour identifier les secrétagogues de peptide YY (PYY) et composés utiles dans le traitement des conditions modulées de secrétagogues BY (PYY) et composés utiles dans le traitement des conditions par PYY
PE20100156A1 (es) * 2008-06-03 2010-02-23 Boehringer Ingelheim Int Tratamiento de nafld
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
BRPI0916997A2 (pt) 2008-08-06 2020-12-15 Boehringer Ingelheim International Gmbh Inibidor de dpp-4 e seu uso
US20110190322A1 (en) * 2008-08-14 2011-08-04 Boehringer Ingelheim International Gmbh Purin derivatives for use in the treatment of fab-related diseases
CN102149407A (zh) 2008-09-10 2011-08-10 贝林格尔.英格海姆国际有限公司 治疗糖尿病和相关病症的组合疗法
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
BRPI0923121A2 (pt) 2008-12-23 2015-08-11 Boehringer Ingelheim Int Formas salinas de compostos orgânico
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
AR077642A1 (es) 2009-07-09 2011-09-14 Arena Pharm Inc Moduladores del metabolismo y el tratamiento de trastornos relacionados con el mismo
ES2548913T3 (es) 2009-09-11 2015-10-21 Probiodrug Ag Derivados heterocíclicos como inhibidores de glutaminil ciclasa
CN102753161A (zh) 2009-11-27 2012-10-24 贝林格尔.英格海姆国际有限公司 基因型糖尿病患者利用dpp-iv抑制剂例如利拉利汀的治疗
JP6026284B2 (ja) 2010-03-03 2016-11-16 プロビオドルグ エージー グルタミニルシクラーゼの阻害剤
JP5688745B2 (ja) 2010-03-10 2015-03-25 プロビオドルグ エージー グルタミニルシクラーゼ（ｑｃ、ｅｃ２．３．２．５）の複素環阻害剤
JP2013523819A (ja) 2010-04-06 2013-06-17 アリーナ ファーマシューティカルズ， インコーポレイテッド Ｇｐｒ１１９レセプターのモジュレーターおよびそれに関連する障害の処置
WO2011131748A2 (fr) 2010-04-21 2011-10-27 Probiodrug Ag Nouveaux inhibiteurs
WO2011138421A1 (fr) 2010-05-05 2011-11-10 Boehringer Ingelheim International Gmbh Combinaison thérapeutique
EP3124041A1 (fr) 2010-06-24 2017-02-01 Boehringer Ingelheim International GmbH Traitement du diabète
WO2012035548A1 (fr) * 2010-09-13 2012-03-22 Advinus Therapeutics Private Limited Composés purine utilisés en tant que promédicaments des antagonistes du récepteur a2b de l'adénosine, leur procédé de préparation et leurs applications médicales
KR101871011B1 (ko) 2010-09-22 2018-06-25 아레나 파마슈티칼스, 인크. Ｇｐｒ１１９ 수용체의 조절제 및 그와 관련된 장애의 치료
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
WO2012088682A1 (fr) * 2010-12-29 2012-07-05 Shanghai Fochon Pharmaceutical Co Ltd. Dérivés de la 2-(3-aminopipéridin-1-yle)-[1,2,4] triazolo [1,5-c] pyrimidine-5,7 (3h,6h)-dione en tant qu'inhibiteurs de la dipeptidylpeptidase iv(dpp-iv)
WO2012123563A1 (fr) 2011-03-16 2012-09-20 Probiodrug Ag Dérivés de benzimidazole en tant qu'inhibiteurs de la glutaminyl cyclase
WO2012135570A1 (fr) 2011-04-01 2012-10-04 Arena Pharmaceuticals, Inc. Modulateurs du récepteur gpr119 et traitement de troubles qui lui sont associés
WO2012145361A1 (fr) 2011-04-19 2012-10-26 Arena Pharmaceuticals, Inc. Modulateurs du récepteur gpr119 et traitement de troubles liés à celui-ci
WO2012145604A1 (fr) 2011-04-22 2012-10-26 Arena Pharmaceuticals, Inc. Modulateurs du récepteur gpr119 et traitement de troubles liés à celui-ci
US20140038889A1 (en) 2011-04-22 2014-02-06 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
WO2012170702A1 (fr) 2011-06-08 2012-12-13 Arena Pharmaceuticals, Inc. Modulateurs du récepteur gpr119 et traitement de troubles associés à celui-ci
US9051329B2 (en) 2011-07-05 2015-06-09 Merck Sharp & Dohme Corp. Tricyclic heterocycles useful as dipeptidyl peptidase-IV inhibitors
ES2713566T3 (es) 2011-07-15 2019-05-22 Boehringer Ingelheim Int Derivado de quinazolina dimérico sustituido, su preparación y su uso en composiciones farmacéuticas para el tratamiento de la diabetes de tipo I y II
WO2013055910A1 (fr) 2011-10-12 2013-04-18 Arena Pharmaceuticals, Inc. Modulateurs du récepteur gpr119 et traitement de troubles associés
WO2013097052A1 (fr) * 2011-12-30 2013-07-04 Abbott Laboratories Inhibiteurs de bromodomaine
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
WO2013171167A1 (fr) 2012-05-14 2013-11-21 Boehringer Ingelheim International Gmbh Dérivé de xanthine en tant qu'inhibiteur de dpp-4 pour l'utilisation dans le traitement de troubles associés aux podocytes et/ou un syndrome néphrotique
WO2013174767A1 (fr) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh Dérivé de xanthine en tant qu'inhibiteur de la dpp-4 à utiliser dans la modification de l'apport alimentaire et dans la régulation des préférences alimentaires
CN103709163B (zh) * 2012-09-29 2016-12-21 齐鲁制药有限公司 黄嘌呤衍生物、其制备方法及用途
WO2014074668A1 (fr) 2012-11-08 2014-05-15 Arena Pharmaceuticals, Inc. Modulateurs de gpr119 et traitement de troubles associés à ceux-ci
AU2013361694B2 (en) * 2012-12-20 2017-10-26 Merck Sharp & Dohme Corp. Substituted imidazopyridines as HDM2 inhibitors
CN105358154A (zh) 2013-05-10 2016-02-24 尼普斯阿波罗有限公司 Acc抑制剂和其用途
WO2014182950A1 (fr) * 2013-05-10 2014-11-13 Nimbus Apollo, Inc. Inhibiteurs de l'acc et utilisations associées
WO2014182951A1 (fr) 2013-05-10 2014-11-13 Nimbus Apollo, Inc. Inhibiteurs de l'acc et utilisations associées
EP2994138A4 (fr) 2013-05-10 2016-12-28 Nimbus Apollo Inc Inhibiteurs de l'acc et utilisations associées
AR096758A1 (es) * 2013-06-28 2016-02-03 Abbvie Inc Inhibidores cristalinos de bromodominios
ES2950384T3 (es) 2014-02-28 2023-10-09 Boehringer Ingelheim Int Uso médico de un inhibidor de DPP-4
JP2017527606A (ja) * 2014-09-18 2017-09-21 サノビオン ファーマシューティカルズ インクＳｕｎｏｖｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． 三環系誘導体
CA2979033A1 (fr) 2015-03-09 2016-09-15 Intekrin Therapeutics, Inc. Methodes de traitement de la steatose hepatique non alcoolique et/ou de la lipodystrophie
JP6901976B2 (ja) * 2015-06-25 2021-07-14 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング キサンチンをベースとする化合物の調製方法
JP2019517542A (ja) 2016-06-10 2019-06-24 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング リナグリプチンおよびメトホルミンの組合せ
US11253508B2 (en) 2017-04-03 2022-02-22 Coherus Biosciences, Inc. PPARy agonist for treatment of progressive supranuclear palsy
EP3461819B1 (fr) 2017-09-29 2020-05-27 Probiodrug AG Inhibiteurs de la glutaminyl-cyclase
CN108299436B (zh) * 2018-02-09 2020-01-17 上海慈瑞医药科技股份有限公司 黄嘌呤类化合物及其药物组合物和应用
EP4225742A1 (fr) 2020-10-05 2023-08-16 Enliven Therapeutics, Inc. Composés de 5- et 6-azaindole pour l'inhibition de tyrosine kinases bcr-abl

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US219178A (en) * 1879-09-02 Improvement in steam-pressure regulators
US100199A (en) * 1870-02-22 Improvement in ditcher and grader
US122228A (en) * 1871-12-26 Improvement in head-blocks
GB8515934D0 (en) * 1985-06-24 1985-07-24 Janssen Pharmaceutica Nv (4-piperidinomethyl and-hetero)purines
GB9906714D0 (en) 1999-03-23 1999-05-19 Ferring Bv Compositions for improving fertility
AU2001268958B2 (en) 2000-07-04 2006-03-09 Novo Nordisk A/S Heterocyclic compounds, which are inhibitors of the enzyme dpp-iv
PT1757606E (pt) * 2001-02-24 2009-05-26 Boehringer Ingelheim Pharma Utilização de derivados de xantina como produto farmacêutico, bem como seu processo de preparação
EP1399124B1 (fr) * 2001-06-11 2007-10-10 Firmenich Sa Emulsion parfumee transparente et stable
WO2003004496A1 (fr) 2001-07-03 2003-01-16 Novo Nordisk A/S Derives de purine inhibiteurs de dpp-iv pour le traitement du diabete
EP1338595B1 (fr) * 2002-02-25 2006-05-03 Eisai Co., Ltd. Dérivés de Xanthines servant d'inhibiteurs de DPP-IV
EP1514552A4 (fr) * 2002-06-06 2008-04-02 Eisai R&D Man Co Ltd Nouveau derive d'imidazole fondu
US7569574B2 (en) * 2002-08-22 2009-08-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Purine derivatives, the preparation thereof and their use as pharmaceutical compositions
MXPA05003252A (es) * 2002-09-26 2005-07-05 Eisai Co Ltd Farmaco de combinacion.
US7109192B2 (en) * 2002-12-03 2006-09-19 Boehringer Ingelheim Pharma Gmbh & Co Kg Substituted imidazo-pyridinones and imidazo-pyridazinones, the preparation thereof and their use as pharmaceutical compositions
NZ540495A (en) 2002-12-04 2007-09-28 Eisai R&D Man Co Ltd 1,3-Dihydro-imidazole fused-ring compound
JPWO2004096806A1 (ja) 2003-04-30 2006-07-13 大日本住友製薬株式会社 縮合イミダゾール誘導体
US7169926B1 (en) * 2003-08-13 2007-01-30 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
WO2005053695A1 (fr) 2003-12-04 2005-06-16 Eisai Co., Ltd. Agent preventif ou therapeutique de la sclerose en plaques

Also Published As

Publication number Publication date
HK1078869A1 (en) 2006-03-24
JP4420334B2 (ja) 2010-02-24
JP3675813B2 (ja) 2005-07-27
KR100985160B1 (ko) 2010-10-05
TWI273104B (en) 2007-02-11
CN1931859A (zh) 2007-03-21
US20090018331A1 (en) 2009-01-15
US20060063787A1 (en) 2006-03-23
AU2003241960B2 (en) 2009-07-30
US20060100199A1 (en) 2006-05-11
CN100348599C (zh) 2007-11-14
US7772226B2 (en) 2010-08-10
RU2297418C9 (ru) 2009-01-27
EP1514552A4 (fr) 2008-04-02
CA2485641A1 (fr) 2003-12-18
BR0311697A (pt) 2005-03-22
JP2005145951A (ja) 2005-06-09
HK1100219A1 (en) 2007-09-14
PL374007A1 (en) 2005-09-19
TW200408639A (en) 2004-06-01
AU2003241960A1 (en) 2003-12-22
EP1514552A1 (fr) 2005-03-16
RU2004139111A (ru) 2005-08-10
MXPA04012226A (es) 2005-04-08
JPWO2003104229A1 (ja) 2005-10-06
CA2485641C (fr) 2010-12-14
NZ536794A (en) 2007-04-27
US20040116328A1 (en) 2004-06-17
CN1675208A (zh) 2005-09-28
RU2297418C2 (ru) 2007-04-20
IS7625A (is) 2005-01-04
KR20050005544A (ko) 2005-01-13
IL165178A0 (en) 2005-12-18
CN100469778C (zh) 2009-03-18
ZA200500041B (en) 2006-06-01
WO2003104229A1 (fr) 2003-12-18

Similar Documents

Publication Publication Date Title
NO20050054L (no) Nye, kondenserte imidazolderivater
NO20064089L (no) Kondensert ring 4-oksopyrimidinderivat
NO20074071L (no) Hydrazinometyl, hydrozonometyl og 5-leddete heterocykliske forbindelser som virker som MTOR inhibitorer og anvendelse derav som anti-cancer midler
BG106073A (en) Quinoline derivatives as inhibitors of mek enzymes
MY153045A (en) Oxopyrazine derivative and herbicide
TW200633991A (en) Chemical compounds
IL164487A0 (en) 3-Heteroaryl substituted 5-methyloxymethyl isoxazolines used as herbicides
MXPA05003193A (es) Compuesto de adenina novedoso y uso del mismo.
AP1902A (en) N-aryl-2-oxazolidinone-5-carboxamides and their derivatives and their use as antibacterials
NO20054224L (no) Nye 2-pyridinkarboksamidderivater
ATE164575T1 (de) Substituierte aromatische verbindungen als c. amp phosphodiesterase-und tnf-hemmer
WO2008114819A1 (fr) Nouveau composé d'adénine
NO20092770L (no) Nye aminopyrimidinderivater som PLK1-inhibitorer
BR0315405A (pt) Compostos inibidores da integrase tricìclica pré-organizados
NO20051047L (no) Fremgangsmate og mellomprodukter for fremstilling av tienopyrrolderivater
FI942635A (fi) Piperatsiinijohdannaiset 5HT1A-antagonisteina
DK1008592T3 (da) Cykliske amidderivater, som inhiberer cathepsin K
BR9913405A (pt) Composto heterocìclico que contenha oxigênio, e, inibidor de fosfodiesterase (pde) iv.
DE69828284D1 (de) Naphthyridinderivate oder salze davon
HUP0003942A2 (hu) Helyettesített 3,3-diamino-2-propén-nitrilek, előállításuk és alkalmazásuk
MY161992A (en) Novel tetrahydroisoquinoline derivative
EA199901096A1 (ru) Цианогуанидины в качестве ингибиторов пролиферации клеток
NO971687D0 (no) Diazepinoindoler som forsfodiesterase IV-inhibitorer
NO20051028L (no) Substituerte tiaziner som materialbeskyttelsesmidler
ATE449773T1 (de) Homomorpholinoxazolidinone als antibakterielle mittel

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application